SCHEMBL367345

SCHEMBL367345

COC1CCc2ccccc2C1=O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 1/20 0.55
MAPT P10636 1/20 0.55
TSHR P16473 1/20 0.55
HSD17B10 Q99714 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
CYP19A1 P11511 3/20 0.51
ACHE P22303 2/20 0.46
CES1 P23141 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTR2C P28335 3/20 0.42
SIGMAR1 Q99720 3/20 0.42
DRD2 P14416 2/20 0.42
HTR2A P28223 2/20 0.42
HTR2B P41595 2/20 0.42
IDO1 P14902 1/20 0.41
HTR1A P08908 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL15903300 0.98 KDM4E (0.54) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL6947877 0.90 CYP2A6 (0.46) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL31217406 0.82 KDM4E (0.49) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL5472936 0.82 KDM4E (0.41) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL1567503 0.81 ACHE (0.58) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL29850498 0.81 ACHE (0.58) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL30437408 0.81 KDM4E (0.51) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL19899145 0.80 KDM4E (0.64) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL30661168 0.80 KDM4E (0.64) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL10711625 0.80 KDM4E (0.50) KDM4EALDH1A1MAPTTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114436790-B Synthesis method of 6-methoxy-1-tetralone 浙江仙居君业药业有限公司 2023-05-05 CN disclosed
CN-114591727-A Organic long-afterglow luminescent material, preparation and application 中国科学院上海有机化学研究所 2022-06-07 CN disclosed
CN-114436790-A Synthesis method of 6-methoxy-1-tetralone 浙江仙居君业药业有限公司 2022-05-06 CN disclosed
US-10259794-B2 Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives CEPHALON, INC. (US) 2019-04-16 US disclosed
EP-3237408-B1 METHODS FOR PREPARING FUSED BICYCLIC 2, 4-DIAMINOPYRIMIDINE DERIVATIVES CEPHALON INC (US) 2018-10-31 EP disclosed
US-20170369451-A1 METHODS FOR PREPARING FUSED BICYCLIC 2, 4-DIAMINOPYRIMIDINE DERIVATIVES CEPHALON, INC. 2017-12-28 US disclosed
CN-107434813-A Display 诺瓦尔德股份有限公司 2017-12-05 CN disclosed
EP-3237408-A1 METHODS FOR PREPARING FUSED BICYCLIC 2, 4-DIAMINOPYRIMIDINE DERIVATIVES Cephalon, Inc. (US) 2017-11-01 EP disclosed
CN-104247070-B Display device 诺瓦尔德股份有限公司 2017-04-12 CN disclosed
WO-2016105529-A1 METHODS FOR PREPARING FUSED BICYCLIC 2, 4-DIAMINOPYRIMIDINE DERIVATIVES CEPHALON, INC. (US) 2016-06-30 WO disclosed
EP-0256849-A1 Aromatization process ETHYL CORPORATION (US) 1988-02-24 EP disclosed
CN-87104970-A The amino-5,6,7 that replaces, 8-tetralyl oxo acetate its preparation method and as the purposes of medicine 1988-02-03 CN disclosed
EP-0179855-A4 DOPAMINE AGONISTS. NELSON RES & DEV COMPANY (US) 1986-08-21 EP disclosed
EP-0179855-A1 DOPAMINE AGONISTS. NELSON RES & DEV (US) 1986-05-07 EP disclosed
WO-1985004582-A1 NOVEL DOPAMINE AGONISTS NELSON RESEARCH AND DEVELOPMENT COMPANY (US) 1985-10-24 WO disclosed
EP-0150192-A4 BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS. RORER INTERNAT OVERSEAS INC (US) 1985-09-16 EP disclosed
US-4540691-A Dopamine agonists and use thereof NELSON RESEARCH & DEVELOPMENT CO. (US) 1985-09-10 US disclosed
EP-0150192-A1 BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS. RORER INT OVERSEAS (US) 1985-08-07 EP disclosed
WO-1984004247-A1 BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES RORER INT OVERSEAS (US) 1984-11-08 WO disclosed
EP-0106486-A2 Improvements in or relating to novel octahydrobenz(f)isoquinolines ELI LILLY AND COMPANY (US) 1984-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369451-A1 METHODS FOR PREPARING FUSED BICYCLIC 2, 4-DIAMINOPYRIMIDINE DERIVATIVES DPYD, LIG4, CEP170 KDM4E 353/4885ALDH1A1 1904/4885MAPT 2618/4885
US-10259794-B2 Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives DPYD, LIG4, CEP170 KDM4E 353/4885ALDH1A1 1904/4885MAPT 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.